Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05550207 · ClinicalTrials.gov registry record · Phase 3
Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)
A Phase 3 study of Migraine, sponsored by Axsome Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT05550207: Completed Phase 3 study of Migraine, sponsored by Axsome Therapeutics.
NCT05550207 is a Phase 3 study of Migraine that has completed, run by Axsome Therapeutics. The registered enrollment target is 100 participants, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05550207, a Phase 3 study of Migraine, has completed, sponsored by Axsome Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, open-label trial to evaluate the efficacy and safety of AXS-07 in subjects with migraine attacks and prior inadequate response to oral CGRP inhibitors.
Primary Outcome
Absence of headache pain and without the use of rescue medication.
Conditions Studied
Interventions
- DRUG AXS-07 (meloxicam-rizatriptan)
Study Locations (20)
Florida
- Clinical Research Site - DeLand
- Clinical Research Site - Hallandale
- Clinical Research Site - Hollywood
- Clinical Research Site - Miami
- Clinical Research Site - Ormond Beach
- Clinical Research Site - Oviedo
- Clinical Research Site - Pensacola
- Clinical Research Site - Winter Park
California
- Clinical Research Site - Colton
- Clinical Research Site - Fullerton
- Clinical Research Site - La Jolla
- Clinical Research Site - Los Angeles
- Clinical Research Site - Sherman Oaks
Massachusetts
- Clinical Research Site - Boston
- Clinical Research Site - North Dartmouth
Connecticut
- Clinical Research Site - Stamford
Georgia
- Clinical Research Site - Stockbridge
Indiana
- Clinical Research Site - Avon
Nevada
- Clinical Research Site - Las Vegas
New Mexico
- Clinical Research Site - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2024-11-27 |
| Phase | Phase 3 |
What the finished NCT05550207 record still lists
NCT05550207 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which AXS-07 (meloxicam-rizatriptan) is the first listed.
NCT05550207 names 20 study sites across 8 states, led by Florida, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05550207 about?
NCT05550207 is a clinical study titled "Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)". This is a multicenter, open-label trial to evaluate the efficacy and safety of AXS-07 in subjects with migraine attacks and prior inadequate response to oral CGRP inhibitors.
What is the current status of trial NCT05550207?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2022-08-31. Estimated completion is 2024-11-27.
What conditions does trial NCT05550207 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT05550207?
The interventions under investigation include: AXS-07 (meloxicam-rizatriptan) (DRUG).
Who is sponsoring clinical trial NCT05550207?
This trial is sponsored by Axsome Therapeutics, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05550207 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05550207's enrollment target sits among peer trials
100 58th of 102 higher than 42 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
RECRUITING · Phase 3
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RECRUITING · Phase 3
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RECRUITING · Phase 3
-
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
RECRUITING · Phase 3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI